JP2024519079A5 - - Google Patents

Info

Publication number
JP2024519079A5
JP2024519079A5 JP2023571820A JP2023571820A JP2024519079A5 JP 2024519079 A5 JP2024519079 A5 JP 2024519079A5 JP 2023571820 A JP2023571820 A JP 2023571820A JP 2023571820 A JP2023571820 A JP 2023571820A JP 2024519079 A5 JP2024519079 A5 JP 2024519079A5
Authority
JP
Japan
Prior art keywords
triol
ene
ethynylandrosta
pharmaceutical composition
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519079A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027294 external-priority patent/WO2022245532A1/en
Publication of JP2024519079A publication Critical patent/JP2024519079A/ja
Publication of JP2024519079A5 publication Critical patent/JP2024519079A5/ja
Pending legal-status Critical Current

Links

JP2023571820A 2021-05-18 2022-05-02 神経変性状態の治療のための組成物 Pending JP2024519079A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163189880P 2021-05-18 2021-05-18
US63/189,880 2021-05-18
PCT/US2022/027294 WO2022245532A1 (en) 2021-05-18 2022-05-02 Compositions for treatment of neurodegenerative conditions

Publications (2)

Publication Number Publication Date
JP2024519079A JP2024519079A (ja) 2024-05-08
JP2024519079A5 true JP2024519079A5 (https=) 2025-05-14

Family

ID=84141848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571820A Pending JP2024519079A (ja) 2021-05-18 2022-05-02 神経変性状態の治療のための組成物

Country Status (7)

Country Link
US (1) US20240108636A1 (https=)
EP (1) EP4341271A4 (https=)
JP (1) JP2024519079A (https=)
AU (1) AU2022275684A1 (https=)
CA (1) CA3218191A1 (https=)
MX (1) MX2023013616A (https=)
WO (1) WO2022245532A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054452A1 (en) * 2022-09-06 2024-03-14 Biovie Inc. Methods for the treatment of mild cognitive impairment
WO2025155561A1 (en) * 2024-01-16 2025-07-24 Biovie Inc. Methods of treating long covid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015763A1 (en) * 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
DK2273994T3 (en) * 2008-04-03 2016-02-01 Neurmedix Inc PHARMACEUTICAL FORMS OF A MEDICINE

Similar Documents

Publication Publication Date Title
US10912754B2 (en) Methods and compositions for treating excessive sleepiness
JP5386173B2 (ja) 閉経前の性的欲求障害の治療のためのフリバンセリンの使用
JP2005537268A5 (https=)
JP2009536176A (ja) 閉経後の性的欲求障害の治療のためのフリバンセリンの使用
TW200829244A (en) Therapeutic combinations 482
JP2024519079A5 (https=)
JP2002520362A5 (https=)
RU2007123565A (ru) Композиции разагилина, распадающиеся в ротовой полости
CA2919078A1 (en) Treatment of pruritic conditions mediated through histamine h-4 receptors
JP2020533296A5 (https=)
US9226924B2 (en) Methods of treating or preventing neuropathic pain
CN104013638A (zh) 当药黄素及其衍生物的用途
JP2021517128A (ja) レボドパ分割用量組成物および使用
PT1628652E (pt) Combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão
CN110267657B (zh) 氨基甲酸酯化合物用于预防、缓解或治疗震颤或震颤综合征的用途
CN110833540B (zh) 一种柳酚咖敏片及其制备方法
EP3954374A1 (en) Pharmaceutical combination of pimozide and methotrexate and use thereof
WO2016125109A1 (en) Pharmaceutical composition for the treatment of obesity
US20050228052A1 (en) Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine
EP2783685B1 (en) Use of levo-oxiracetam in preparation of medicines for preventing or treating coma
JP3865450B2 (ja) パーキンソニズム治療剤
Perspectivism et al. Lofepramine (antidepressant): uses, indications and side effects
US20100173879A1 (en) Use of a compound antagonist to the nk2 receptors of neurokinin a for the preparation of drugs useful for preventing and treating of sexual dysfunction
CN119523988A (zh) 一种治疗神经系统疾病的药物组合物
CN115887462A (zh) 一种口服药物组合物